0001144204-17-000105.txt : 20170103 0001144204-17-000105.hdr.sgml : 20170103 20170103132943 ACCESSION NUMBER: 0001144204-17-000105 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170103 DATE AS OF CHANGE: 20170103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Elrod Marcus W CENTRAL INDEX KEY: 0001684249 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28508 FILM NUMBER: 17501119 MAIL ADDRESS: STREET 1: 33 AVENUE DU DR. GEORGES LEVY CITY: VENNISSIEUX STATE: I0 ZIP: 69200 4 1 v455599_form4.xml FORM 4 X0306 4 2016-12-31 1 0001012477 AVADEL PHARMACEUTICALS PLC AVDL 0001684249 Elrod Marcus W C/O FLAMEL TECHNOLOGIES S.A. 33 AVENUE DU DR. GEORGES LEVY VENISSIEUX I0 69200 FRANCE 0 1 0 0 See Remarks ADSs 2016-12-31 4 D 0 3400 0 D 0 D Stock Option (right to buy) 13.59 2016-12-31 4 D 0 100000 0 D 2026-08-10 ADSs 100000 0 D Stock Option (right to buy) 10.4 2016-12-31 4 D 0 22000 0 D 2026-12-14 ADSs 22000 0 D The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts. On 12/31/16, Flamel Technologies S.A. ("Flamel") merged with and into Avadel Pharmaceuticals plc ("Avadel"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person is filing this Form 4 solely to report dispositions of Flamel securities as a result of the Merger. The reporting person will also file a Form 3 to reflect his or her new status as a director and/or executive officer of Avadel, and a new Form 4 evidencing his or her acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in this Form 4 or the acquisitions to be reported in the new Form 4. Represents 3,400 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date. Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively. Options become exercisable as to 25,000 ADSs on each of August 10, 2017, 2018, 2019 and 2020, provided that the reporting person continues to be employed by the issuer or an affiliate thereof. Options become exercisable as to 5,500 ADSs on each of the first four anniversaries after the 12/14/2016 grant date. VP, Sales. The reporting person is submitting this Form 4 with respect to the disposition of securities in Flamel Technologies S.A. As described in Footnote 2 above, on December 31, 2016 Avadel Pharmaceuticals plc became the successor by merger to Flamel. In connection with such merger, the company information on the SEC's EDGAR system for CIK # 0001012477 (which number was formerly associated with Flamel) has been changed to reflect Avadel as the SEC filing company. Therefore, all Form 4s submitted via EDGAR after December 31, 2016 with respect to Flamel or Avadel will reflect Avadel's name, address, and ticker symbol. /s/ Phillandas T. Thompson, as attorney-in-fact for Marcus W. Elrod 2016-12-31